Statement of Reclassification

The SH‑1 Molecule is hereby transitioned out of all prior cosmetic‑active positioning. Effective immediately, SH‑1 will no longer be described, marketed, or framed as a cosmetic‑grade surface active. Instead, SH‑1 enters a formal pre‑clinical developmental phase focused on mechanistic assays, receptor‑binding studies, and controlled biological evaluation.

This decision is not reactive, corrective, or the result of any adverse finding. It represents a strategic elevation of SH‑1’s scientific identity. The molecule’s structural sophistication — specifically its tetracyclic AR‑antagonist scaffold, competitive displacement geometry, and follicular microenvironment logic — warrants an investigational pathway that reflects its true clinical potential.

Rationale: Distinguishing SH‑1 from Unvalidated Actives

Cosmetic actives typically operate within a domain where mechanism claims require minimal empirical proof and where unvalidated ingredients proliferate. Ingredients such as JXL069 occupy this category: marketed aggressively while remaining mechanistically unverified and lacking receptor‑level or metabolic evidence.

Remaining within the cosmetic category would place SH‑1 in the same speculative tier, regardless of its theoretical rigor. The scientific narrative of SH‑1 demands a rigorous validation pathway that distinguishes it from unassayed cosmetic ingredients.

Pre-Clinical & Investigational Roadmap

SH‑1 commits to the following empirical evaluation milestones:

Theoretical Continuity Within the SMI Framework

While SH‑1 is no longer positioned as a surface cosmetic active, its structural identity remains fully intact within the SMI (Structured Multiversal Interactions) theoretical framework via the SH‑1 Reality Kernel model.

• A tetracyclic AR‑antagonist scaffold
• A competitive presence model
• A microenvironmental regulator
• A geometric docking narrative